Compare DCBO & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCBO | AQST |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.3M | 809.3M |
| IPO Year | 2020 | 2018 |
| Metric | DCBO | AQST |
|---|---|---|
| Price | $21.05 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $35.57 | $10.00 |
| AVG Volume (30 Days) | 98.3K | ★ 3.0M |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.42 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $236,691,000.00 | $43,397,000.00 |
| Revenue This Year | $13.00 | N/A |
| Revenue Next Year | $8.37 | $51.39 |
| P/E Ratio | $26.72 | ★ N/A |
| Revenue Growth | ★ 13.16 | N/A |
| 52 Week Low | $20.20 | $2.12 |
| 52 Week High | $50.80 | $7.55 |
| Indicator | DCBO | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 55.29 |
| Support Level | $20.47 | $5.73 |
| Resistance Level | $21.37 | $6.17 |
| Average True Range (ATR) | 0.97 | 0.38 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 12.59 | 88.24 |
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.